Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.

Abstract:

OBJECTIVES:We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. METHODS:Time to treatment discontinuation (TD) and virological failure (VF) and their predictors were assessed in a multicenter cohort of HIV-1 infected patients, starting lamivudine + dolutegravir after reaching viral suppression. Secondary objective was the evaluation of changes in lipid profile, renal and immunological functions at week 48. RESULTS:We enrolled 206 patients (72.8% male, with 51 years median age), who mainly switched their antiretroviral therapy for simplification (32.5%) or drug toxicity (54.5%). The estimated probability of maintaining virological suppression at 48 and 96 weeks was 98.2% and 95.1%, respectively. VF was independently predicted by cumulative time on antiretroviral therapy. The estimated probability of remaining on lamivudine plus dolutegravir was 86.7% and 80.5% at week 48 and 96, respectively. A significant improvement in immunological function (CD4 count and CD4/CD8 ratio) was evidenced at week 48, as well as a decrease in total cholesterol/HDL ratio, triglycerides and estimated glomerular filtration rate. CONCLUSIONS:Lamivudine plus dolutegravir was effective in maintaining viral suppression in our cohort and led to an improvement in metabolic and immunologic functions.

journal_name

HIV Med

journal_title

HIV medicine

authors

Borghetti A,Baldin G,Lombardi F,Ciccullo A,Capetti A,Rusconi S,Sterrantino G,Latini A,Cossu MV,Gagliardini R,De Luca A,Di Giambenedetto S

doi

10.1111/hiv.12611

subject

Has Abstract

pub_date

2018-03-24 00:00:00

eissn

1464-2662

issn

1468-1293

pub_type

杂志文章
  • High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey.

    abstract:BACKGROUND:Southern African countries have borne the brunt of the HIV/AIDS pandemic. Monitoring epidemiological dynamics is critical to identify the populations at greatest risk of infection and to guide control strategies. METHODS:A cross-sectional community-based study to determine age- and sex-specific HIV prevalen...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01018.x

    authors: González R,Munguambe K,Aponte J,Bavo C,Nhalungo D,Macete E,Alonso P,Menéndez C,Naniche D

    更新日期:2012-11-01 00:00:00

  • Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy.

    abstract:OBJECTIVES:The extent to which highly active antiretroviral therapy (HAART) affects human papillomavirus (HPV) acquisition and clearance in HIV-infected women is not well understood. We sought to describe high-risk HPV detection and clearance rates over time since HAART initiation, based on time-varying HIV viral load ...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2011.00979.x

    authors: Kang M,Cu-Uvin S

    更新日期:2012-07-01 00:00:00

  • Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

    abstract:OBJECTIVES:We evaluated the emergence of drug resistance in patients failing first-line regimens containing one nonnucleoside reverse transcriptase inhibitor (NNRTI) administered with zidovudine (ZDV) + lamivudine (the ZDV group) or non-thymidine analogues (non-TAs) (tenofovir or abacavir, + lamivudine or emtricitabine...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12044

    authors: Santoro MM,Sabin C,Forbici F,Bansi L,Dunn D,Fearnhill E,Boumis E,Nicastri E,Antinori A,Palamara G,Callegaro A,Francisci D,Zoncada A,Maggiolo F,Zazzi M,Perno CF,Ceccherini-Silberstein F,Mussini C

    更新日期:2013-10-01 00:00:00

  • The role of brain biopsy in the clinical management of HIV-related focal brain lesions.

    abstract:OBJECTIVES:Up to 20% of HIV-related focal brain lesion (FBL) diagnoses cannot be determined without invasive procedures. In such cases, brain biopsy is an important step in the evaluation algorithm. The aims of this study were to describe the clinical outcomes of patients with FBL, the proportion of diagnoses confirmed...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12646

    authors: Acosta MC,Kundro M,Viloria G,Peressín Paz A,Morello F,Latorre F,Seoane E,Toibaro J,Losso M

    更新日期:2018-11-01 00:00:00

  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract:OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12831

    authors: Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期:2020-07-01 00:00:00

  • Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.

    abstract:OBJECTIVES:Human leukocyte antigen (HLA)-B(*)5701 is strongly associated with developing a hypersensitivity reaction to abacavir (ABC) in White and Hispanic subjects. Across the UK, limited data exist on HLA-B(*)5701 prevalence in HIV-1-infected subjects. We determined HLA-B(*)5701 prevalence in the general HIV-1-infec...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2009.00762.x

    authors: Orkin C,Sadiq ST,Rice L,Jackson F,UK EPI team.

    更新日期:2010-03-01 00:00:00

  • Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study.

    abstract:OBJECTIVES:The aim of the study was to evaluate prospectively the usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in investigation of fever of unknown origin (FUO) in HIV-positive patients and to determine whether HIV viraemia impacts on FDG-PET/CT performance. METHODS:Th...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12030

    authors: Martin C,Castaigne C,Tondeur M,Flamen P,De Wit S

    更新日期:2013-09-01 00:00:00

  • A global survey of HIV-positive people's attitudes towards cure research.

    abstract:OBJECTIVES:Involvement of people living with HIV (PLHIV) in the design of HIV cure studies is important, given the potential risks to participants. We present results of an international survey of PLHIV to define these issues and inform cure research. METHODS:PLHIV were recruited in June-November 2014 through HIV webs...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12391

    authors: Simmons R,Kall M,Collins S,Cairns G,Taylor S,Nelson M,Fidler S,Porter K,Fox J,Collaborative HIV Eradication of viral Reservoirs (CHERUB) Survey collaboration.

    更新日期:2017-02-01 00:00:00

  • Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

    abstract:BACKGROUND:ODIN (once-daily darunavir in treatment-experienced patients) was a 48-week, phase III, randomized, open-label trial comparing once-daily (qd) darunavir/ritonavir (DRV/r) 800/100 mg with twice-daily (bid) DRV/r 600/100 mg, both with an optimized background regimen [OBR; at least two nucleoside reverse transc...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12024

    authors: Sension M,Cahn P,Domingo P,Hodder S,Opsomer M,Lathouwers E,Van de Casteele T,Tomaka F

    更新日期:2013-08-01 00:00:00

  • The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

    abstract::Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00279.x

    authors: Tung MY,Mandalia S,Bower M,Gazzard B,Nelson M

    更新日期:2005-05-01 00:00:00

  • Psychological wellbeing and use of alcohol and recreational drugs: results of the British HIV Association (BHIVA) national audit 2017.

    abstract:OBJECTIVES:The aim of this national audit was to assess adherence of services providing HIV care in the UK to national standards and guidelines regarding psychological support and the assessment of alcohol and recreational drug use (including chemsex drugs) in people living with HIV (PLWH). METHODS:Participating sites...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12744

    authors: Parry S,Curtis H,Chadwick D,British HIV Association Audit and Standards Sub-Committee.

    更新日期:2019-07-01 00:00:00

  • Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE s

    abstract:OBJECTIVES:We assessed whether changes at week 12 in markers of bone turnover, inflammation, and immune activation were associated with clinically important (≥ 5%) bone mineral density (BMD) loss from baseline to week 48 at the proximal femur (hip) and lumbar spine in the SECOND-LINE study. METHODS:We measured concent...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12882

    authors: Mwasakifwa GE,Amin J,White CP,Center JR,Kelleher A,Boyd MA

    更新日期:2020-09-01 00:00:00

  • Associations of marijuana with markers of chronic lung disease in people living with HIV.

    abstract:OBJECTIVES:The relationship between marijuana use and markers of chronic lung disease in people living with HIV (PLWH) is poorly understood. METHODS:We performed a cross-sectional analysis of the Examinations of HIV-Associated Lung Emphysema (EXHALE) study, including 162 HIV-positive patients and 138 participants with...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12966

    authors: Wenger DS,Triplette M,Shahrir S,Akgun KM,Wongtrakool C,Brown ST,Kim JW,Soo Hoo GW,Rodriguez-Barradas MC,Huang L,Feemster LC,Zifodya J,Crothers K

    更新日期:2021-02-01 00:00:00

  • Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.

    abstract:OBJECTIVES:Apricitabine (ATC) is a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with significant antiviral activity in vitro, including activity against HIV-1 with reverse transcriptase mutations that confer resistance to other NRTIs. ATC has shown promising antiviral activity and good...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2010.00887.x

    authors: Cahn P,Altclas J,Martins M,Losso M,Cassetti I,Cooper DA,Cox S

    更新日期:2011-07-01 00:00:00

  • Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.

    abstract:OBJECTIVES:People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug-drug interactions (DDIs) in PWHIV. METHODS:The Climate-HIV electronic recording system was used to cross-sectionally analyse records from PWHIV aged ≥ 18 years attending four UK HIV units with a curr...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12879

    authors: Okoli C,Schwenk A,Radford M,Myland M,Taylor S,Darley A,Barnes J,Fox A,Grimson F,Reeves I,Munshi S,Croucher A,Boxall N,Benn P,Paice A,van Wyk J,Khoo S

    更新日期:2020-09-01 00:00:00

  • Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy.

    abstract:BACKGROUND:Mucocutaneous manifestations such as oral candidiasis (OC) and seborrheic dermatitis (SD) are very common HIV-related opportunistic events and are usually initial markers of immunodeficiency. AIM:The purpose of this study was to evaluate the efficacy of highly active antiretroviral therapy (HAART) in the re...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1468-1293.2004.00185.x

    authors: Dunic I,Vesic S,Jevtovic DJ

    更新日期:2004-01-01 00:00:00

  • Utilization of absolute monocyte counts to predict cardiovascular events in people living with HIV.

    abstract:OBJECTIVES:Cardiovascular risk is increased in people living with HIV (PLWH). In HIV-uninfected populations, total absolute monocyte count (AMC) has been shown to be predictive of future cardiovascular events (CVEs). We sought to determine whether AMC predicts CVEs in PLWH independent of established and HIV-related car...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13018

    authors: Bogorodskaya M,Lyass A,Mahoney TF,Borowsky LH,Sen P,Swirski FK,Srinivasa S,Longenecker CT,Massaro JM,D'Agostino RB Sr,Triant VA

    更新日期:2020-12-08 00:00:00

  • Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.

    abstract:BACKGROUND:The world-wide AIDS epidemic is reflected in Western Europe in an increasing number of HIV-infected persons who originate from Africa. We describe the characteristics and response to antiretroviral therapy (ART) of HIV-infected patients born in Africa and living in France. METHODS:Analysis of data from the ...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00447.x

    authors: Breton G,Lewden C,Spire B,Salmon D,Brun-Vézinet F,Duong M,Allavena C,Leport C,Salamon R,APROCO COPILOTE ANRS CO8 Study Group.

    更新日期:2007-04-01 00:00:00

  • Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

    abstract:BACKGROUND:More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS:In 2005, 34 departments prospectively recorded all dea...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00686.x

    authors: Rosenthal E,Salmon-Céron D,Lewden C,Bouteloup V,Pialoux G,Bonnet F,Karmochkine M,May T,François M,Burty C,Jougla E,Costagliola D,Morlat P,Chêne G,Cacoub P,Mortavic\/Mortalité 2005 Study Group.

    更新日期:2009-05-01 00:00:00

  • Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

    abstract:OBJECTIVE:The aim of the study was to evaluate the predictive value of clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), for the development of lactic acidosis (LA) and symptomatic hyperlactataemia (SHL). METHODS:In a substu...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00934.x

    authors: Feeney ER,Chazallon C,O'Brien N,Meiffrédy V,Goodall RL,Aboulker JP,Cooper DA,Yeni P,Mallon PW,INITIO Trial International Co-ordinating Committee.

    更新日期:2011-11-01 00:00:00

  • Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients.

    abstract:OBJECTIVES:In the case of coinfection with HIV and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), hepatic disease progression is often accelerated, with higher rates of liver cirrhosis and liver-related mortality. We aimed to evaluate the performance of the rapid tests used routinely to detect HBV surface anti...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12158

    authors: Hønge B,Jespersen S,Medina C,Té D,da Silva Z,Ostergaard L,Laursen A,Wejse C,Krarup H,Erikstrup C,Bissau HIV cohort study group.

    更新日期:2014-10-01 00:00:00

  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract::Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1046/j.1468-1293.2000.00027.x

    authors: Hermans P

    更新日期:2000-07-01 00:00:00

  • Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

    abstract:OBJECTIVES:Efforts are needed to improve informed consent of participants in research. The Strategic Timing of AntiRetroviral Therapy (START) study provides a unique opportunity to study the effect of length and complexity of informed consent documents on understanding and satisfaction among geographically diverse part...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12230

    authors: Denning E,Sharma S,Smolskis M,Touloumi G,Walker S,Babiker A,Clewett M,Emanuel E,Florence E,Papadopoulos A,Sánchez A,Tavel J,Grady C,International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Grou

    更新日期:2015-04-01 00:00:00

  • Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.

    abstract:OBJECTIVES:Whether treatment-experienced HIV-1-infected patients with an acquired K103N mutation after failing nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens can be treated with rilpivirine is unknown. The aim of this pilot study was to evaluate the efficacy of rilpivirine/tenofovir/emtricitabine in HIV...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12157

    authors: Rokx C,Verbon A,Rijnders BJ

    更新日期:2014-11-01 00:00:00

  • Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.

    abstract:OBJECTIVE:More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. METHODS:Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in al...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00650.x

    authors: Smith CJ,Phillips AN,Dauer B,Johnson MA,Lampe FC,Youle MS,Tyrer M,Staszewski S

    更新日期:2009-01-01 00:00:00

  • The association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study.

    abstract:OBJECTIVES:The aim of the study was to investigate the association of adiposity with longitudinal kidney function change in 544 HIV-infected persons in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) cohort over 5 years of follow-up. METHODS:The regional distribution of muscle and adipose ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12196

    authors: Malkina A,Scherzer R,Shlipak MG,Bacchetti P,Tien PC,Grunfeld C,Kosmiski L,Peralta CA

    更新日期:2015-03-01 00:00:00

  • Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

    abstract:OBJECTIVE:Study 903 was a 144-week, randomized, double-blind, active-controlled study of tenofovir disoproxil fumarate (TDF) therapy in treatment-naive HIV-1-infected patients. Patients received either TDF (n = 299) or stavudine (d4T) (n = 301) with lamivudine (3TC) and efavirenz (EFV). Resistance analyses were perform...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2006.00404.x

    authors: Margot NA,Lu B,Cheng A,Miller MD,Study 903 Team.

    更新日期:2006-10-01 00:00:00

  • The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review.

    abstract:OBJECTIVES:The aim of the study was to assess the currently available evidence concerning the management of dyslipidaemias in HIV-infected individuals treated with antiretroviral therapy. METHODS:Randomized trials, published within the 5 years preceding 5 October 2005, were identified in PubMed Medline, Embase, and Th...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/j.1468-1293.2007.00480.x

    authors: McGoldrick C,Leen CL

    更新日期:2007-09-01 00:00:00

  • Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection.

    abstract:OBJECTIVES:To study the impact of highly active antiretroviral therapy (HAART) on isotype switching and avidity maturation of HIV-1-specific immunoglobulin G (IgG) in patients with primary HIV-1 infection (PHI). METHODS:We studied the emergence and the evolution of anti-HIV IgG antibodies by quantitative immunoblottin...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2006.00406.x

    authors: Adalid-Peralta L,Grangeot-Keros L,Rudent A,Ngo-Giang-Huong N,Krzysiek R,Goujard C,Deveau C,Le Gall M,Meyer L,Emilie D,Rouzioux C

    更新日期:2006-11-01 00:00:00

  • Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort.

    abstract:BACKGROUND:GB virus type C (GBV-C) viraemia is associated with a beneficial outcome in HIV-infected individuals in several though not all studies. GBV-C viraemia was examined in a matched case-control study of 133 HIV-infected pregnant women who transmitted HIV to their infants ('cases') and 266 non-transmitting contro...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00510.x

    authors: Handelsman E,Cheng I,Thompson B,Hershow R,Mofenson LM,Hollinger FB,Chen KT,Burchett SK,Klinzman D,Stapleton JT,Women and Infants Transmission Study Group (WITS).

    更新日期:2007-11-01 00:00:00